Experts believe a wider spat with Europe would be much more damaging than the current tit-for-tat with China.Traderead more
After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Markets pay particular attention to Italy's spending, given its public debt pile. This stands at above 130% of its growth rate, one of the highest in the world.Politicsread more
Flight bookings to Hong Kong have fallen 10%, hit by the unrest in the city, said Alan Joyce, the chief executive of Australian carrier Qantas Airways.Airlinesread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The Senate confirmed the nomination of former drug company executive Alex Azar as head of the U.S. Health and Human Services Department on Wednesday.
Azar's long-expected approval as HHS secretary puts him in a charge of a department with a trillion-dollar budget that oversees the massive Medicare and Medicaid health coverage systems, drug regulatory bodies, disease-fighting agencies and the ever-controversial Obamacare health reform law.
The Senate voted 55-43 in favor of Azar's appointment.
The 50-year-old Azar is a veteran of HHS, having served for two years as deputy secretary and before that as general counsel of the department, both during the administration of President George W. Bush.
In 2017, the Yale Law grad ended a five-year stint as president of the U.S. division of pharmaceuticals giant Eli Lilly and Co.
Democratic senators during Azar's recent confirmation hearings highlighted the price increases of Lily's drugs while he was at the company, and given that history were skeptical of his claims to intend to fight rising drug costs as HHS chief.
Azar is the first person with a pharmaceutical industry background to lead the health agency.
And two former HHS chiefs under Bush, Tommy Thompson and Mike Leavitt, wrote in The Hill that Azar "has the necessary experience, skills, motivation and integrity" to run the department.
HHS had been without a secretary since September, when Trump's original pick for the job, Dr. Tom Price, resigned amid controversy over his use of private and expensive charter jets for official travel.
Price's departure came while Trump and his Republican allies in Congress were pushing legislation that sought to repeal and replace key parts of the Affordable Care Act, as Obamacare is formally known.
Those efforts failed, repeatedly, in the Senate. But the recently passed tax law did effectively eliminate, starting in 2019, the ACA requirement that most Americans have some form of Obamacare-compliant health coverage or pay a fine.
Azar opposes the ACA, which has led to criticism of his nomination from groups that support Obamacare.
On Wednesday, The Washington Post reported that the Trump administration is looking into expanding access to hardship exemptions from Obamacare's coverage mandate, making it easier for people to avoid the existing penalty for not having insurance.
Azar, who also clerked for late conservative Supreme Court Justice Antonin Scalia, also has contributed to politicians who oppose abortion rights.
After the Senate Finance Committee voted Tuesday to advance Azar's nomination to the full Senate, the abortion rights group NARAL Pro-Choice blasted the move.
"It is sad, but not surprising, that Donald Trump is so desperate to install another anti-choice ideologue at HHS, an agency that's critical for women's healthcare. HHS has a duty to protect the health, rights, and reproductive freedom of women all across America, and Azar's clear and consistent anti-choice record should disqualify him from such an influential position," said NARAL spokeswoman Kaylie Hanson Long.